Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Moderna forecasts COVID sales decline as costs rise, shares fall

Published 02/23/2023, 07:53 AM
Updated 02/23/2023, 03:15 PM
© Reuters. FILE PHOTO: Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration

By Leroy Leo

(Reuters) - Moderna (NASDAQ:MRNA) Inc on Thursday forecast declining COVID-19 vaccine sales and rising costs for 2023, raising concerns the U.S. biotech company could post a loss this year, and its shares fell 7%.

Moderna forecast $6 billion in costs for the year, $1 billion more than the revenue it expects to take in from sales of the COVID shot.

The sales forecast implies a "possible EPS net loss" this year compared to the huge profit its COVID vaccines drove during its peak, Jefferies analyst Michael Yee said in a note.

However, there is a potential for positive cash flow this year if Moderna is able to get more advanced purchase agreements for its COVID shots, Yee said. Moderna expects additional sales from markets including the United States, Europe and Japan.

Moderna also reported a fourth-quarter profit that missed Wall Street expectations by a wide margin, saying the results were hurt by a newly-disclosed royalty payment to the U.S. National Institutes of Health (NIH) related to development of the COVID-19 vaccine as well as other costs.

The company will make a low-single-digit percentage royalty payment to the NIH on COVID vaccines sales going forward, it said, and expects to spend $4.5 billion on research and development this year.

The company posted a profit of $3.61 per share, well below analysts' estimates of $4.68, according to Refinitiv data.

Oppenheimer analyst Hartaj Singh also said the company could have "negative earnings" in 2023, putting the share price at risk this year and next.

Sales of the COVID vaccine, Moderna's only commercial product, were expected to fall sharply this year from $18.4 billion in 2022 as much global demand for initial shots and boosters has been met, while governments and other agencies cut purchases.

Moderna is developing mRNA vaccines for skin cancer, flu and respiratory syncytial virus (RSV) that if approved would significantly lessen its reliance on the COVID shots.

It plans to file for regulatory approval of the influenza vaccine this year, but does not expect sales for the 2023 flu season.

© Reuters. FILE PHOTO: Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration

Moderna's fourth-quarter profit was below expectations because it paid a catch-up royalty of around $400 million to the NIH related to a long-standing patent rights dispute over the COVID-19 vaccine. The company had not previously disclosed an agreement for a payment that was set in December.

Moderna's quarterly profit also took a hit from over $950 million in write-downs and charges related to surplus inventory, cancellations and a shift to Omicron-targeting bivalent boosters in many countries.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.